Vertex Pharmaceuticals has grown revenue 9.8% a year over three years and 14% a year over five, with earnings per share compounding at 9.9%. Revenue growth, 3-year annual rate: +9.8% (Biotechnology median +21%). Revenue growth, 5-year rate: +14%, growth has slowed since the five-year average. Earnings per share, 3-year rate: +9.9%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 18, FY2008 to FY2025, as filed.

VRTXVertex Pharmaceuticals

HealthcareUSD

$547.27

$366.5452 weeks$553.04

Is it growing?

Is VRTX growing?

Vertex Pharmaceuticals has grown revenue 9.8% a year over three years and 14% a year over five, with earnings per share compounding at 9.9%.

+9.8%

Revenue growth, 3-year annual rate · Biotechnology median +21% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +14%
Revenue growth, 5-year rate · +9.8% over three · growth has slowed since the five-year average
Earnings per share, 3-year rate: +9.9%
Earnings per share, 3-year rate · revenue +9.8% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 18
Years of annual history on file · FY2008 to FY2025, as filed